Related Experiment Videos
Mild to moderate hyperhomocysteinaemia in cardiovascular disease
A S De Vriese1, J H De Sutter, M De Buyzere
1Division of Nephrology, University Hospital, Gent, Belgium. an.devriese@rug.ac.be
Insights
High homocysteine levels, linked to vascular disease, can often be normalized with B-group vitamins. However, the impact of this vitamin treatment on cardiovascular outcomes is still unknown.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Nutritional Science
Background:
- Elevated serum homocysteine is an independent risk factor for atherosclerotic and thrombotic vascular disease.
- Hyperhomocysteinaemia is commonly caused by methylenetetrahydrofolatereductase (MTHFR) thermolabile variant and folate deficiency.
- Homocysteine contributes to vascular damage via oxygen radical generation and promotes a prothrombotic state.
Purpose of the Study:
- To investigate the impact of B-group vitamin administration on normalizing homocysteine levels.
- To evaluate the effect of homocysteine normalization on cardiovascular outcomes.
Main Methods:
- Review of existing literature on homocysteine, MTHFR, folate status, and cardiovascular disease.
- Analysis of studies reporting homocysteine level normalization with B-group vitamin therapy.
- Assessment of data regarding cardiovascular event rates in patients treated with B-group vitamins for hyperhomocysteinaemia.
Main Results:
- Hyperhomocysteinaemia is a significant risk factor for vascular disease.
- B-group vitamin administration effectively normalizes homocysteine levels in most patients.
- The effect of homocysteine normalization on actual cardiovascular outcomes remains undefined in current research.
Conclusions:
- While B-group vitamins can normalize homocysteine levels, their clinical benefit on cardiovascular outcomes requires further investigation.
- Understanding the precise role of homocysteine in vascular disease progression is crucial.
- Further clinical trials are needed to define the therapeutic efficacy of homocysteine-lowering strategies.
Abstract:
Elevated serum levels of homocysteine, a sulphur-containing amino acid, are increasingly recognized as an independent risk factor for atherosclerotic and thrombotic vascular disease. Presence of a thermolabile variant of methylenetetrahydrofolatereductase and an inadequate folate status are the most common causes of hyperhomocysteinaemia. Homocysteine damages the vessel wall mainly through generation of oxygen radicals and creates a prothrombotic environment. In the majority of cases, normalization of homocysteine levels can be achieved with administration of vitamins of the B-group. The effect of this treatment on cardiovascular outcome, however, remains undefined.